Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

U.S. FDA Panel Recommends Gilead's Quad for HIV

May 14, 2012

A Food and Drug Administration advisory panel on Friday voted 13-1 to recommend Gilead Sciences Inc.'s Quad pill for people with HIV who have never been treated. However, the independent experts said patients taking the drug should be monitored for possible kidney problems, and they urged more research to assess the safety of Quad for women, who were under-represented in clinical trials.

The panel's sole "no" voter said data on potential kidney problems and on women's health were too limited to justify approval. "There are plenty of alternatives to Quad," said Dr. Michelle Estrella of Johns Hopkins University School of Medicine. "There's no huge hurry in approving this drug before the outstanding studies are completed."

View Full Article


  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
More News on Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir)

Reader Comments:

Comment by: Ayanda D. (South Africa) Sun., May. 20, 2012 at 12:43 pm EDT
The Body is use by the drugs companies. It is not independent from the pharmaceautical companies.
It serve the interest of these drugs companies not the public
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement